In the Molecular Diagnostics segment, virology grew by 180 percent year over year, LightMix systems grew by 189 percent, and the point-of-care molecular business grew by 152 percent year over year, Schinecker said on the call.Ĭentralized and Point of Care Solutions revenues decreased 7 percent to CHF 7.27 billion in 2020 from CHF 7.82 billion in 2019 and contributed 53 percent to diagnostics sales. Growth was driven mostly by COVID-19 testing, offsetting the decline in routine testing as a result of the pandemic, Roche said. Schinecker said he expects both the COVID-19 portfolio and the core business to grow in 2021, and added that Roche plans to launch 17 assays in 2021, which will drive growth in the future.įor full-year 2020, Molecular Diagnostics revenues grew 78 percent to CHF 3.76 billion from CHF 2.11 billion in 2019 and contributed 27 percent to 2020 diagnostics sales. The firm's current capacity is 20 million tests per month.īy the end of 2020 there were more than 1,0000 high-throughput Cobas 6800/8800 instruments in place, and during the year more than twice the number that Roche had projected were installed. He added that production capacity for SARS-CoV-2 tests has ramped up significantly, and the firm expects to provide 40 million tests per month by the end of the first quarter and 70 million per month by the end of the first half of 2021. Roche Diagnostics CEO Thomas Schinecker said on a conference call to discuss the earnings that the antigen test would be "another weapon to diagnose people quickly. Roche has filed for EUA for the antigen test, it said in a statement. For the fourth quarter, diagnostics sales increased 20 percent to CHF 4.13 billion from CHF 3.44 billion in the same quarter in 2019.ĭuring the fourth quarter, Roche received Emergency Use Authorization from the US Food and Drug Administration for its Elecsys Anti-SARS-CoV-2 S antibody test, which quantitatively measures antibodies and can measure a person's vaccine-induced immune response, and the company received CE marking for its Elecsys SARS-CoV-2 antigen test to support high-volume testing of COVID-19 patients. Meanwhile, Roche Diagnostics had sales of CHF 13.79 billion in 2020, up 6 percent from CHF 12.95 billion in 2019. The pharmaceuticals division had CHF 44.53 billion in 2020 revenues, down 8 percent from CHF 48.52 billion in 2019. Overall, Roche reported CHF 58.32 billion ($64.66 billion) in revenues for the year, down 5 percent from CHF 61.47 in 2019, but up 1 percent at constant exchange rates, the firm said.
NEW YORK – Roche on Thursday reported a 6 percent increase in sales of its diagnostics division for full-year 2020, driven primarily by its COVID-19 testing portfolio. Note: This story has been updated with additional information from the company's earnings call.
0 kommentar(er)
